Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels

The Prevalence of Metabolic Syndrome in Patients With Psoriasis and Psoriatic Arthritis and Its Correlation With Disease Severity and Serum Omentin-1 and Visfatin Levels

In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined. At the same time, the levels of omentin and visfatin adipokines associated with metabolic syndrome and obesity will be measured by measuring the disease severity (by PASI psoriasis, clinical activity score for psoriatic arthritis). The patients who accepted to participate in the study , who were admitted to the dermatology outpatient clinic were included in the study. For the blood tests required after the examination, 2 tubes of blood will be taken for the measurement of omentin and visfatin. 80 psoriasis, 40 psoriatic arthritis and 60 healthy volunteers were planned to be studied. AHA / NHLBI, 2005 (revised ATP III criteria) criterion for the diagnosis of metabolic syndrome will be used. Omentin and visfatin levels are compared with the severity of the disease for psoriasis and psoriatic arthritis, and it will be examined whether it is proinflammatory or antiinflammatory.

Study Overview

• Status: Completed
• Conditions: Metabolic Syndrome; Psoriasis Vulgaris; Psoriatic Arthritis
• Intervention / Treatment: Diagnostic test: omentin, visfatin

• Study Type: Interventional
• Enrollment (Actual): 180
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Istanbul, Turkey, 34722
    • Istanbul Medeniyet University
  • Istanbul, Turkey, 34722
    • Istanbul Medeniyet University, Department of dermatology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients followed up for psoriasis and psoriatic arthritis in dermatology and rheumatology clinic
2. Patients older than 18 years
3. Patients who accept dermatological and rheumatic examination
4. Patients not receiving systemic treatment related to the disease in the last 1 month

Exclusion Criteria:

1. Patients with autoimmune and rheumatic diseases other than psoriasis and psoriatic arthritis
2. Patients under 18 years
3. Patients who do not accept dermatological and rheumatic examination Patients receiving systemic therapy for the last 1 month pregnant and nursing moms

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: psoriasis vulgaris,; patients who have only psoriasis vulgaris	Diagnostic test: omentin, visfatin; diagnostic blood test
OTHER: psoriatic arthritis; patients who have psoriatic arthritis	Diagnostic test: omentin, visfatin; diagnostic blood test
OTHER: healthy control; healthy people	Diagnostic test: omentin, visfatin; diagnostic blood test

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
omentin	Omentin (omentin 1-2) is a specific protein that consists of amino acids released from vascular vessels	6 months
visfatin	Visfatin is an insulin-like protein that binds to insulin receptors produced mostly from visceral fatty tissue.	6 months

Collaborators and Investigators

• Sponsor: Istanbul Medeniyet University

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 15, 2019
• Primary Completion (ACTUAL): June 1, 2019
• Study Completion (ACTUAL): June 14, 2019

Study Registration Dates

• First Submitted: April 24, 2019
• First Submitted That Met QC Criteria: April 26, 2019
• First Posted (ACTUAL): April 30, 2019

Study Record Updates

• Last Update Posted (ACTUAL): June 17, 2019
• Last Update Submitted That Met QC Criteria: June 14, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Keywords: omentin; metabolic syndrome; psoriatic arthritis; psoriasis vulgaris; visfatin
• Additional Relevant MeSH Terms: Pathologic Processes; Glucose Metabolism Disorders; Metabolic Diseases; Skin Diseases; Disease; Joint Diseases; Musculoskeletal Diseases; Skin Diseases, Papulosquamous; Insulin Resistance; Hyperinsulinism; Spinal Diseases; Bone Diseases; Spondylarthropathies; Spondylarthritis; Spondylitis; Syndrome; Arthritis; Psoriasis; Metabolic Syndrome; Arthritis, Psoriatic
• Other Study ID Numbers: DDagdelen

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No